New York, New York (PRWEB) February 22, 2014
A Byetta lawsuit (http://www.byettalawsuit.com) Plaintiff has withdrawn her motion seeking the consolidation of all federal claims involving allegations that the Type 2 diabetes drug caused patients to develop thyroid cancer, Bernstein Liebhard LLP reports. According to a new Motion filed with the U.S. Judicial Panel on Multidistrict Litigation on February 18, 2014, the Plaintiff’s request is being withdrawn to facilitate further discussions with Defendants related to the proposed consolidation. (In re Byetta Thyroid Cancer Products Liability Litigation, MDL No. 2525 (JPML))
“Our Firm has received numerous inquiries from Byetta patients who have been diagnosed with thyroid cancer, as well as pancreatic cancer and pancreatitis, allegedly as result of this medication. We will continue to monitor this litigation closely,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta lawsuit evaluations to patients who may have been harmed by this drug.
Byetta and Pancreatic Cancer
According to the February 18th motion, at least 36 Byetta lawsuits involving thyroid cancer are now pending in federal courts around the country. Prior to filing the Motion to Withdraw, the Plaintiff had requested that all federally-filed thyroid cancer claims be transferred to U.S. District Court Judge Anthony J. Battaglia in the Southern District of California. According to court documents, Judge Battaglia is already presiding over a consolidated proceeding for product liability claims that allege Byetta and other diabetes drugs called incretin mimetics are associated with an increased risk of pancreatic cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
Lawsuits alleging a connection between Byetta and pancreatic cancer have been mounting since March 2013, when the U.S. Food & Drug Administration (FDA) announced that it was investigating the safety of all incretin mimetics after a small study indicated they might cause precancerous changes to the cells of the pancreas. The following month, the Institute for Safe Medicine Practices published an analysis which found that as a class, incretin mimetics were more likely to be named in pancreatic cancer reports than any other category of diabetes medications. The same study also revealed that Byetta had been named in 63 reports of pancreatitis, 71 reports of pancreatic cancer, and 14 reports of thyroid cancer made to the FDA in a single year.
Byetta users who may have been harmed by this drug could be eligible to file their own Byetta lawsuit. Find out more about the alleged association between Byetta and pancreatic cancer, pancreatitis and thyroid cancer at Bernstein Liebhard LLP’s website. For a free legal review, please call 800-511-5092.
*ismp.org/quarterwatch/pdfs/2012Q3.pdf, ISMP, April 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com